Letters

RESEARCH LETTER

National Trends in the US Public’s Likelihood of Getting a COVID-19 Vaccine—April 1 to December 8, 2020

The coronavirus disease 2019 (COVID-19) pandemic is causing enormous morbidity and mortality across the US and is disproportionately affecting racial/ethnic minority populations and elderly persons. High acceptance of COVID-19 vaccines will be instrumental to ending the pandemic.

Four cross-sectional internet surveys1-4 (3 using convenience samples1,3,4) from April2 and May1,3,4 2020 found that 58% to 69% of adults intended to get vaccinated against COVID-19, with higher percentages reported in April2 than in May.1,3,4 These studies did not track the same individuals over time, making it difficult to assess whether intent to get vaccinated has truly declined.

We analyzed biweekly survey data from a nationally representative longitudinal study to describe changes over time in the public’s likelihood of getting a COVID-19 vaccine and across demographic subgroups.

Methods | The Understanding America Study (UAS) is a probability-based internet panel survey of approximately 9000 noninstitutionalized US adults.5 Respondents are recruited using address-based sampling, allowing for valid statistical inferences and avoiding coverage problems from convenience web panels. Internet-enabled tablets are provided if needed.

Beginning March 10, 2020, the entire UAS panel has been invited to participate in biweekly tracking surveys about COVID-19; consenting respondents are invited on a rolling basis (590 invited daily) to participate in each wave and have 2 weeks to complete surveys.

Beginning April 1-14 and continuing through November 25-December 8, we asked: “How likely are you to get vaccinated for coronavirus once a vaccine is available to the public?” Response options (very unlikely, somewhat unlikely, somewhat likely, very likely, unsure) were dichotomized into “somewhat or very likely” vs all others. A multivariable Poisson regression model with robust standard errors was used to estimate adjusted risk ratios (aRRs) and 95% CIs of the likelihood of getting vaccinated. Changes in likelihood of getting a COVID-19 vaccine (overall and by demographic subgroups) were analyzed using linear regression models with cluster-robust standard errors at the respondent level. Analyses (SAS version 9.4) accounted for survey sampling weights. Statistical significance was defined as a 95% CI that did not cross 1. The UAS panel oversamples residents of Los Angeles County and, to a lesser extent, residents of the rest of California; survey sampling weights adjust for this.

Table. Percentage of Adults Who Stated in April 2020 and December 2020 That They Were Somewhat or Very Likely to Get Vaccinated for COVID-19, and Change Over Time

<table>
<thead>
<tr>
<th>Demographic characteristic</th>
<th>April 2020 survey (April 1-14); likely to get a vaccine, % (95% CI)</th>
<th>December 2020 survey (November 25–December 8); likely to get a vaccine, % (95% CI)</th>
<th>Adjusted risk ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>74.1 (72.4-75.8)</td>
<td>56.2 (54.4-58.1)</td>
<td>-17.9 (-20.0 to -15.8)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men</td>
<td>79.1 (76.8-81.5)</td>
<td>62.3 (59.6-65.0)</td>
<td>-16.9 (-20.0 to -13.8)</td>
</tr>
<tr>
<td>Women</td>
<td>69.5 (67.1-71.9)</td>
<td>50.6 (48.1-53.1)</td>
<td>-18.9 (-21.8 to -16.0)</td>
</tr>
<tr>
<td>Age group, y</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18-49</td>
<td>69.1 (66.5-71.7)</td>
<td>50.9 (48.2-53.7)</td>
<td>-18.2 (-21.4 to -15.0)</td>
</tr>
<tr>
<td>50-64</td>
<td>76.7 (73.8-79.6)</td>
<td>57.0 (53.7-60.4)</td>
<td>-19.7 (-23.5 to -15.8)</td>
</tr>
<tr>
<td>≥65</td>
<td>83.8 (81.0-86.6)</td>
<td>69.1 (65.7-72.5)</td>
<td>-14.7 (-18.6 to -10.8)</td>
</tr>
<tr>
<td>Race/ethnicity*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White</td>
<td>77.8 (75.9-79.6)</td>
<td>58.6 (56.5-60.8)</td>
<td>-19.1 (-21.5 to -16.8)</td>
</tr>
<tr>
<td>Black</td>
<td>50.7 (44.7-56.7)</td>
<td>37.6 (32.0-43.2)</td>
<td>-0.7 (0.6-0.8)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>73.1 (67.8-78.3)</td>
<td>52.7 (47.1-58.2)</td>
<td>-20.4 (-27.2 to -13.6)</td>
</tr>
<tr>
<td>Asian</td>
<td>90.9 (86.1-95.7)</td>
<td>80.6 (73.9-87.2)</td>
<td>-10.3 (-18.5 to -2.2)</td>
</tr>
<tr>
<td>Education</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>High school completion or less</td>
<td>67.0 (63.7-70.2)</td>
<td>47.6 (44.3-50.9)</td>
<td>-19.4 (-23.4 to -15.4)</td>
</tr>
<tr>
<td>Some college</td>
<td>70.5 (67.4-73.6)</td>
<td>50.2 (46.9-53.5)</td>
<td>-20.3 (-24.3 to -16.4)</td>
</tr>
<tr>
<td>Bachelor’s degree or higher</td>
<td>85.0 (82.8-87.1)</td>
<td>70.3 (67.5-73.0)</td>
<td>-14.7 (-17.6 to -11.9)</td>
</tr>
</tbody>
</table>

Note: Sample size varied across waves.


* Mutually adjusted for all the demographic factors in the table.

b Ordinary least squares with cluster-robust standard errors was used to assess change over the time frame, which accounted for correlation of repeated measures and survey sampling weights.

c Online panel members self-reported race/ethnicity from a set of survey questions. Data are not presented for American Indian/Alaska Native, Native Hawaiian and Other Pacific Islander, and other non-Hispanic multiracial groups due to small sample sizes.
Participants provided written informed consent and the University of Southern California’s institutional review board approved this study.

Results | To date, 8167 UAS panel respondents have consented to participate in the biweekly tracking surveys. The number of consenting respondents who completed the surveys varied across 2-week periods (range: 5259 to 6139; range of completion rate per 2-week period: 75%-97%). During November 25–December 8 (Table), the self-reported likelihood of getting COVID-19 vaccination was lower among women than men (51% vs 62%; aRR, 0.9 [95% CI, 0.8-0.9]) and Black vs White individuals (38% vs 59%; aRR, 0.7 [95% CI, 0.6-0.8]), and higher among adults aged 65 years and older vs those 18-49 years (69% vs 51%; aRR, 1.4 [95% CI, 1.3-1.5]) and those with at least a bachelor’s degree vs a high school education or less (70% vs 48%; aRR, 1.5 [95% CI, 1.3-1.6]).

Between April 1-14 and November 25–December 8, the percentage who stated they were somewhat or very likely to get vaccinated declined from 74% to 56% (difference: 18 percentage points [95% CI, 16-20]) (Figure). Significant declines over time in the likelihood of seeking vaccination were observed for both women and men and in all age, racial/ethnic, and educational subgroups.

Discussion | In this nationally representative survey, self-reported likelihood of getting a COVID-19 vaccine declined from 74% in early April to 56% in early December 2020, despite the early November press releases of high vaccine efficacy for 2 vaccines in phase 3 trials, although prior to Emergency Use Authorization. Low likelihood of getting a COVID-19 vaccine among Black individuals and those with lower educational backgrounds is especially concerning because of their disproportionately higher burden from COVID-19 disease.

Study strengths include analyses of change over time within the same group of individuals from a representative online survey panel. Limitations include use of only English- and Spanish-language surveys, self-reported metrics that may not correlate with future behavior, and small sample sizes for certain minority populations.

Educational campaigns to raise the public’s willingness to consider COVID-19 vaccination are needed.

Peter G. Szilagyi, MD, MPH
Kyla Thomas, PhD
Megha D. Shah, MD, MPH, MS
Nathalie Vizueta, PhD
Yan Cui, MD, PhD
Sitaram Vangala, MS
Arie Kapteyn, PhD

Author Affiliations: Department of Pediatrics, University of California, Los Angeles (Szilagyi, Vizueta); Dornsife College of Letters Arts and Sciences Center for Economic and Social Research, University of Southern California, Los Angeles (Thomas, Kapteyn); Los Angeles County Department of Public Health, Office of Health Assessment and Epidemiology, Los Angeles, California (Shah, Cui); Department of Medicine Statistics Core, University of California, Los Angeles (Vangala).

Accepted for Publication: December 21, 2020.

Published Online: December 29, 2020. doi:10.1001/jama.2020.26419

Corresponding Author: Peter G. Szilagyi, MD, MPH, Department of Pediatrics, University of California, Los Angeles, 10833 LeConte, MC 175217, Los Angeles, California 90095 (pszilagyi@mednet.ucla.edu).

Author Contributions: Drs Szilagyi and Kapteyn had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Szilagyi, Shah, Vizueta, Kapteyn.
Acquisition, analysis, or interpretation of data: Szilagyi, Thomas, Shah, Cui, Vangala, Kapteyn.
Drafting of the manuscript: Szilagyi.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Szilagyi, Cui, Vangala.
Obtained funding: Szilagyi, Kapteyn.
Administrative, technical, or material support: Szilagyi, Vizueta.
Supervision: Szilagyi.
Conflict of Interest Disclosures: Dr Szilagyi reported receiving a grant from UCLA David Geffen School of Medicine—Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program for personnel and statistical time. Dr Szilagyi also reported receiving funding from NIH NCATS UCLA CTSI during the conduct of this study. Dr Kapteyn reported receiving funding from University of Southern California (USC) for partial support for the...
USC survey team, grants from Bill & Melinda Gates Foundation for partial support for the UAS survey, grants from the National Institute on Aging for partial support for the UAS survey, and grants from National Science Foundation for partial support for the UAS under the conduct of the study. Dr Thomas reported receiving funding from USC and the National Institute on Aging. No other disclosures were reported.

**Funding/Support:** This work was supported by the UCLA David Geffen School of Medicine—Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research Award Program, the University of Southern California, the Bill & Melinda Gates Foundation, and by federal funds from the National Center for Advancing Translational Sciences (NCATS), National Institutes of Health, through the Clinical and Translational Science Awards (CTSA) Program (grant UL1TR001881), the National Institute on Aging (grant S01AG054580-03), and the National Science Foundation (grant 2028683).

**Role of the Funder/Sponsor:** The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

**Additional Contributions:** We thank Paul Simon, MD, and Rashmi Shetgiri, MD, of the Los Angeles County Department of Public Health for their input on an early draft of this article. Neither of the individuals received compensation for their contributions to the study.


**Hospital Revenue Under Maryland’s Total Cost of Care Model During the COVID-19 Pandemic, March-July 2020**

The outbreak of coronavirus disease 2019 (COVID-19) resulted in large-scale, unprecedented deferment of nonurgent medical and surgical care beginning in mid-March 2020. These volume reductions could threaten hospital solvency, particularly in rural areas and low-resource settings.

Maryland has a distinctive health care payment model. A waiver from the Centers for Medicare & Medicaid Services allows a central body, the Health Services Cost Review Commission (HSCRC), to govern the rates for services and annual global budget for each hospital. Rates are set such that total revenues are anticipated to match each hospital’s planned annual revenue.

To offset revenue losses from deferment of nonurgent care, the HSCRC allowed Maryland hospitals to temporarily increase their inpatient and outpatient service prices by up to 10% to 15% in late March and allowed further increases in inpatient prices up to 20% in May through July 2020.

We aimed to investigate (1) the revenues of Maryland hospitals from March through July 2020 compared with historical trends and (2) whether the option to increase rates was associated with changes to hospital revenues in the state.

**Methods**

We used HSCRC hospital revenue and volume data from January 2018 through July 2020. We calculated total monthly hospital revenue and compared 2020 revenues with 2 counterfactuals: (1) revenues in 2018 and 2019 (dollar amounts adjusted for inflation) and (2) estimated revenues in 2020 under the assumption that prices were held at their February levels, rather than increased in response to COVID-19. To calculate estimated revenue, we applied February 2020 price levels to volumes observed in later months. Hospitals were excluded if monthly revenue was ever missing during follow-up (n = 16). Analysis was stratified by hospital characteristics: urban or rural county designation, teaching status (yes or no), total hospital bed count, and percentage of Medicaid discharges (above or below median at baseline, defined using the 2018 American Hospital Survey). Analysis was conducted using Stata MP, version 16.0 (StataCorp).

**Results**

From February to April 2020, total monthly inpatient revenue of Maryland hospitals decreased from $842 million to $698.6 million (a decline of $143.4 million [17.0%]) (Figure). During the same period, hospital outpatient revenues declined from $601.9 million to $328.0 million (a decline of $273.9 million [45.5%]). April 2020 inpatient revenues were 17.9% to 18.8% lower than in April 2018 and April 2019, while...